Trial · NCT07555470
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470, Phase 2, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma. Trials, record NCT07555470. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07555470
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
- NCT number
- NCT07555470
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Follicular Lymphoma
- Interventions
- Mosunetuzumab, Zeprumetostat
- First posted
- 2026-04-29
- Last updated
- 2026-06-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Complete Response (CR) Rate (Cohort 1 and Cohort 3) | Up to approximately 12 months (From start of treatment until the end of up to 12 cycles of treatment) | The best complete response (CR) rate is defined as the percentage of participants who achieve a complete response during the treatment period, as assessed by the investigator according to the Lugano 2014 classification criteria |
| Primary | 3-Year Event-Free Survival (EFS) Rate (Cohort 2) | Up to 3 years | Event-Free Survival (EFS) is defined as the time from the start of treatment to the first occurrence of any of the following events: progression to high-tumor-burden (HTB) based on GELF criteria, initiation of cytotoxic chemotherapy and/or radiotherapy, histologic transformation, or death from any cause. |
| Secondary | Objective Response Rate (ORR) (Cohorts 1, 2, and 3) | Up to approximately 12 months (end of treatment) | Percentage of participants achieving a Complete Response (CR) or Partial Response (PR) during the treatment period, assessed according to the Lugano 2014 classification |
| Secondary | Rate of Progression of Disease within 24 Months (POD24) (Cohorts 1, 2, and 3) | 24 months | Percentage of participants experiencing disease progression within 24 months from the initiation of treatment |
| Secondary | Progression-Free Survival (PFS) | Up to approximately 5 years | The time from the start of treatment to disease progression or death from any cause. |
| Secondary | Overall Survival (OS) | Up to approximately 5 years | The time from the start of treatment to death from any cause. |
| Secondary | Change From Baseline in EORTC QLQ-C30 Score | Baseline up to approximately 5 years | Evaluated using the EORTC QLQ-C30 questionnaires to assess health-related quality of life and disease-specific symptoms. Scores are transformed to a 0 to 100 scale. For global health status/quality of life and functional scales, higher scores indicate better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptom burden or worse symptoms. |
| Secondary | Change From Baseline in FACT-Lym LYMS Score | Baseline up to approximately 5 years | The Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale (FACT-Lym LYMS) score ranges from 0 to 60, with higher scores indicating better lymphoma-specific quality of life and fewer lymphoma-related symptoms. Evaluated using the FACT-Lym LYMS questionnaires to assess health-related quality of life and disease-specific symptoms. |
| Secondary | Incidence and Severity of Adverse Events (AEs) | Up to approximately 5 years | Safety evaluated by monitoring the incidence and severity of AEs, graded according to the NCI CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07555470
GET https://conductscience.org/api/trials/v1/NCT07555470/registered